Celcuity Inc. (CELC)
| Market Cap | 6.43B +1,458.1% |
| Revenue (ttm) | n/a |
| Net Income | -192.89M |
| EPS | -3.89 |
| Shares Out | 48.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 410,898 |
| Open | 130.80 |
| Previous Close | 132.18 |
| Day's Range | 127.75 - 135.80 |
| 52-Week Range | 10.26 - 151.02 |
| Beta | 0.09 |
| Analysts | Strong Buy |
| Price Target | 169.00 (+28.26%) |
| Earnings Date | May 14, 2026 |
About CELC
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for CELC stock is "Strong Buy." The 12-month stock price target is $169.0, which is an increase of 28.26% from the latest price.
News
Celcuity price target raised to $185 from $165 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Celcuity (CELC) to $185 from $165 and keeps a Buy rating on the shares. With the announcement of Study…
Celcuity price target raised to $175 from $150 at Stifel
Stifel raised the firm’s price target on Celcuity (CELC) to $175 from $150 and keeps a Buy rating on the shares.
Celcuity price target raised to $183 from $150 at Wells Fargo
Wells Fargo raised the firm’s price target on Celcuity (CELC) to $183 from $150 and keeps an Overweight rating on the shares. The firm thought the company’s recent updates were…
Celcuity reports Q1 adjusted EPS (86c) vs. (81c) last year
Net cash used in operating activities for the first quarter of 2026 was $55.1M, compared to $35.9M for the prior year period. “With positive results in both cohorts of the…
Celcuity Earnings Call Transcript: Q1 2026
Q1 2026 saw positive phase III results for gedatolisib in advanced breast cancer, expansion of clinical programs, and full commercial launch readiness. Net loss increased year-over-year, but cash reserves are expected to fund operations through 2027.
Celcuity Earnings release: Q1 2026
Celcuity released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Celcuity Quarterly report: Q1 2026
Celcuity has published its Q1 2026 quarterly earnings report on May 14, 2026.
Notable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Applied Materials (AMAT), consensus $2.68… Celcuity (CELC), consensus (89c)… Figma (FIG), consensus 6c… Boot Barn (...
Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
MINNEAPOLIS, May 14, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid ...
Celcuity announces amendments to VIKTORIA-2 clinical trial of gedatolisib
Celcuity (CELC) announced updates to the Phase 3 VIKTORIA-2 clinical trial of gedatolisib as a first-line treatment for patients with hormone receptor positive, human epidermal growth factor receptor ...
Celcuity's Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients
Development of a gedatolisib formulation for subcutaneous injection is underway; first patent application submitted to the U.S. Patent and Trademark Office Development of a gedatolisib formulation for...
Celcuity Schedules Release of First Quarter 2026 Financial Results and Webcast/Conference Call
MINNEAPOLIS, May 07, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will...
Celcuity price target raised to $189 from $141 at Craig-Hallum
Craig-Hallum analyst Chase Knickerbocker raised the firm’s price target on Celcuity (CELC) to $189 from $141 and keeps a Buy rating on the shares following the company’s announcement of statistically…
Celcuity price target raised to $165 from $135 at Guggenheim
Guggenheim analyst Brad Canino raised the firm’s price target on Celcuity (CELC) to $165 from $135 and keeps a Buy rating on the shares. With the positive VIKTORIA-1 Phase 3…
Celcuity price target raised to $157 from $122 at Needham
Needham raised the firm’s price target on Celcuity (CELC) to $157 from $122 and keeps a Buy rating on the shares. The firm is citing the company announcements that geda…
Celcuity price target raised to $150 from $125 at Stifel
Stifel analyst Stephen Willey raised the firm’s price target on Celcuity (CELC) to $150 from $125 and keeps a Buy rating on the shares. The firm views the “statistically significant…
Celcuity upgraded to Buy from Neutral at H.C. Wainwright
H.C. Wainwright upgraded Celcuity (CELC) to Buy from Neutral with a price target of $165, up from $94. The company announced positive results from the PIK3CA mutant advanced breast cancer…
Celcuity price target raised to $160 from $150 at Citizens
Citizens raised the firm’s price target on Celcuity (CELC) to $160 from $150 and keeps an Outperform rating on the shares. Celcuity’s second Phase 3 success suggests gedatolisib could expand…
Celcuity’s Phase 3 VIKTORIA-1 trial achieves primary endpoint
Celcuity (CELC) announced positive topline results from the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial evaluating gedatolisib plus fulvestrant with or without palbociclib in patient...
Celcuity's Phase 3 VIKTORIA-1 Trial Achieves Primary Endpoint With Clinically Meaningful Improvement in Progression-Free Survival in PIK3CA Mutant Cohort
Detailed data for the gedatolisib triplet and doublet regimens will be presented at a late-breaking abstract oral session at the 2026 ASCO Annual Meeting Detailed data for the gedatolisib triplet and ...
Celcuity trading halted, news pending
16:00 EDT Celcuity (CELC) trading halted, news pending
Celcuity Proxy statement: Proxy filing
Celcuity filed a proxy statement on April 2, 2026, providing details for shareholder voting and corporate governance matters.